Literature DB >> 21481721

Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions.

Lisa K Morikawa1, Mack Roach.   

Abstract

Over the past 15 years, there have been three major advances in the use of external beam radiotherapy in the management of men with clinically localized prostate made. They include: (1) image guided (IG) three-dimensional conformal/intensity modulated radiotherapy; (2) radiation dose escalation; and (3) androgen deprivation therapy. To date only the last of these three advances have been shown to improve overall survival. The presence of occult pelvic nodal involvement could explain the failure of increased conformality and dose escalation to prolong survival, because the men who appear to be at the greatest risk of death from clinically localized prostate cancer are those who are likely to have lymph node metastases. This review discusses the evidence for prophylactic pelvic nodal radiotherapy, including the key trials and controversies surrounding this issue.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481721     DOI: 10.1016/j.ijrobp.2010.11.074

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  30 in total

1.  [Not Available].

Authors:  W Kurre; A Berlis; H-C Diener; J Fiehler; R Gold; C Groden; G F Hamann; J Röther; B Eckert
Journal:  Clin Neuroradiol       Date:  2015-12       Impact factor: 3.649

2.  Prostate cancer: Elective pelvic nodal radiotherapy: is the jury still out?

Authors:  Juanita Crook
Journal:  Nat Rev Urol       Date:  2015-11-24       Impact factor: 14.432

3.  [Radiotherapy with rectangular fields compared to conformal fields. Fewer clinical failures in high-risk prostate cancer patients].

Authors:  A Dal Pra; D M Aebersold
Journal:  Strahlenther Onkol       Date:  2013-12       Impact factor: 3.621

4.  Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Authors:  Mack Roach; Jennifer Moughan; Colleen A F Lawton; Adam P Dicker; Kenneth L Zeitzer; Elizabeth M Gore; Young Kwok; Michael J Seider; I-Chow Hsu; Alan C Hartford; Eric M Horwitz; Kosj Yamoah; Christopher U Jones; Jeff M Michalski; W Robert Lee; Thomas M Pisansky; Rachel Rabinovitch; Marvin Rotman; Rodger M Pryzant; Harold E Kim; Charles R Thomas; William U Shipley; Howard M Sandler
Journal:  Lancet Oncol       Date:  2018-10-10       Impact factor: 41.316

5.  Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?

Authors:  Mack Roach; Kimberly Thomas
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

6.  Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Authors:  Kiri A Sandler; Ryan R Cook; Jay P Ciezki; Ashley E Ross; Mark M Pomerantz; Paul L Nguyen; Talha Shaikh; Phuoc T Tran; Richard G Stock; Gregory S Merrick; David Jeffrey Demanes; Daniel E Spratt; Eyad I Abu-Isa; Trude B Wedde; Wolfgang Lilleby; Daniel J Krauss; Grace K Shaw; Ridwan Alam; Chandana A Reddy; Daniel Y Song; Eric A Klein; Andrew J Stephenson; Jeffrey J Tosoian; John V Hegde; Sun Mi Yoo; Ryan Fiano; Anthony V D'Amico; Nicholas G Nickols; William J Aronson; Ahmad Sadeghi; Stephen C Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Robert E Reiter; Jonathan W Said; Michael L Steinberg; Eric M Horwitz; Patrick A Kupelian; Christopher R King; Amar U Kishan
Journal:  Eur Urol       Date:  2019-04-13       Impact factor: 20.096

7.  Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Authors:  Daniel E Spratt; Hebert A Vargas; Zachary S Zumsteg; Jennifer S Golia Pernicka; Joseph R Osborne; Xin Pei; Michael J Zelefsky
Journal:  Eur Urol       Date:  2016-08-11       Impact factor: 20.096

8.  Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.

Authors:  Paula J Hurley; Debasish Sundi; Brian Shinder; Brian W Simons; Robert M Hughes; Rebecca M Miller; Benjamin Benzon; Sheila F Faraj; George J Netto; Ismael A Vergara; Nicholas Erho; Elai Davicioni; R Jeffrey Karnes; Guifang Yan; Charles Ewing; Sarah D Isaacs; David M Berman; Jennifer R Rider; Kristina M Jordahl; Lorelei A Mucci; Jessie Huang; Steven S An; Ben H Park; William B Isaacs; Luigi Marchionni; Ashley E Ross; Edward M Schaeffer
Journal:  Clin Cancer Res       Date:  2015-10-07       Impact factor: 12.531

Review 9.  Clinical trials involving carbon-ion radiation therapy and the path forward.

Authors:  Ann A Lazar; Reinhard Schulte; Bruce Faddegon; Eleanor A Blakely; Mack Roach
Journal:  Cancer       Date:  2018-10-11       Impact factor: 6.860

Review 10.  Molecular and functional imaging for detection of lymph node metastases in prostate cancer.

Authors:  Ansje Fortuin; Maarten de Rooij; Patrik Zamecnik; Uwe Haberkorn; Jelle Barentsz
Journal:  Int J Mol Sci       Date:  2013-07-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.